Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
IDE196 (Darovasertib) in Combination with Crizotinib As First-line Therapy in Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- IDEAYA Biosciences
- Target Recruit Count
- 420
- Registration Number
- NCT05987332
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Moores Cancer Center, La Jolla, California, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05922904
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyOther: Fludeoxyglucose F-18Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyOther: Questionnaire AdministrationRadiation: Involved-site Radiation Therapy
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1875
- Registration Number
- NCT05675410
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇺🇸USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 44
- Registration Number
- NCT05404945
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
- Conditions
- Leiomyosarcoma
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 360
- Registration Number
- NCT05269355
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The Ohio State University (OSU), Columbus, Ohio, United States
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 146
- Registration Number
- NCT05008224
- Locations
- 🇺🇸
Stanford Cancer Center ( Site 0023), Palo Alto, California, United States
🇺🇸Northwestern Memorial Hospital ( Site 0002), Chicago, Illinois, United States
🇺🇸Texas Oncology-Plano East ( Site 0020), Plano, Texas, United States
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
- Conditions
- Soft Tissue Sarcoma
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Philogen S.p.A.
- Target Recruit Count
- 98
- Registration Number
- NCT04733183
- Locations
- 🇫🇷
Hopital Jean Minjoz, Besançon, France
🇫🇷Institut Bergonié, Bordeaux, France
🇫🇷Centre Jean Perrin, Clermont-Ferrand, France
CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma
- Conditions
- LMS - LeiomyosarcomaUterine Leiomyosarcoma
- Interventions
- Procedure: Cytoreductive SurgeryBehavioral: Functional Assessment of Cancer Therapy (FACT) G questionnaireProcedure: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Kristen Ganjoo
- Target Recruit Count
- 25
- Registration Number
- NCT04727242
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- Radiation: Involved site radiotherapyDrug: Haematopoietic growth factor
- First Posted Date
- 2020-12-28
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1042
- Registration Number
- NCT04685616
- Locations
- 🇺🇸
Stanford University - (Stanford Cancer Institute), Stanford, California, United States
🇺🇸University of Miami School of Medicine, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)
- Conditions
- Hodgkin Lymphoma, Adult
- Interventions
- First Posted Date
- 2020-11-20
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
- Target Recruit Count
- 300
- Registration Number
- NCT04638790
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, OPD-81 Main building, Dr. E Borges Road, Parel 400012, India
🇷🇺The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.